Flor Alvarado

Flor Alvarado

Auto-generated profile, based on publicly available information

Flor Alvarado

Section of Nephrology and Hypertension, John W. Deming Department of Medicine, Tulane University, New Orleans, Louisiana, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
FAFlor Alvarado
Flor Alvarado
CCCarmen Elena Elena Cervantes
Carmen Elena Elena Cervantes
DCDeidra C. Crews
Deidra C. Crews
JBJamie Blanck
Jamie Blanck
FAFawaz Al Ammary
Fawaz Al Ammary
TPTanjala S. Purnell
Tanjala S. Purnell
We conducted a systematic review to assess outcomes in Hispanic donors and explore how Hispanic ethnicity was characterized. We searched PubMed, EMBASE, and Scopus through October 2021. Two reviewers independently screened study titles, abstracts, and full texts; they also qualitatively synthesized results and independently assessed quality of included studies. Eighteen studies met our inclusion criteria. Study sample sizes ranged from 4007 to 143,750 donors and mean age ranged from 37 to 54 years. Maximum follow‐up time of studies varied from a perioperative donor nephrectomy period to 30 years post‐donation. Hispanic donors ranged between 6% and 21% of the donor populations across studies. Most studies reported Hispanic ethnicity under race or a combined race and ethnicity category. Compared to non‐Hispanic White donors, Hispanic donors were not at increased risk for post‐donation mortality, end‐stage kidney disease, cardiovascular disease, non‐pregnancy‐related hospitalizations, or overall perioperative surgical complications. Compared to non‐Hispanic White donors, most studies showed Hispanic donors were at higher risk for diabetes mellitus following nephrectomy; however, mixed findings were seen regarding the risk for post‐donation chronic kidney disease and hypertension. Future studies should evaluate cultural, socioeconomic, and geographic differences within the heterogeneous Hispanic donor population, which may further explain variation in health outcomes.

24 April 2020 in American Journal of Hypertension
Verified
Journal Article
Open access
PDF file
MPMary Carmelle Philogene
Mary Carmelle Philogene
DHDingfen Han
Dingfen Han
FAFlor Alvarado
Flor Alvarado
NFNeal S Fedarko
Neal S Fedarko
AZAlan B Zonderman
Alan B Zonderman
DCDeidra C Crews
Deidra C Crews
We aimed to determine the prevalence of antibodies against angiotensin II type 1 receptor (AT1RAb) in hypertensive adults and elucidate the relation of antihypertensive medication type to blood pressure (BP) among persons with and without AT1RAb. Sera from participants in the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study with hypertension were tested for AT1RAb using a commercial Enzyme-linked immunosorbent assay (ELISA) (One Lambda; positive ≥17 units/ml). BP measurements, uncontrolled BP (systolic BP ≥140 and/or diastolic BP ≥90 mm Hg), and effect of BP medication type were compared for AT1RAb positive (+) vs. negative (−) participants using descriptive statistics and multivariable regression. One hundred and thirty-two (13.1%) participants were AT1RAb+. Compared with AT1RAb−, AT1RAb+ persons were more likely to be white (47% vs. 36.7%; P = 0.03) but had similar comorbid disease burden. In models adjusting for age, sex, and race, AT1RAb+ persons had higher diastolic BP (β = 2.61 mm Hg; SE = 1.03; P = 0.01) compared with AT1RAb− participants. Rates of uncontrolled BP were similar between the groups. AT1RAb+ persons on an angiotensin receptor blocker (ARB; n = 21) had a mean of 10.5 mm Hg higher systolic BP (SE = 4.56; P = 0.02) compared with AT1RAb+ persons using other BP medications. The odds of uncontrolled BP among AT1RAb+ participants on an ARB was 2.05 times that of those on other medications. AT1RAb− persons prescribed an angiotensin-converting enzyme inhibitor (ACEi) had 1.8 mm Hg lower diastolic BP (SE = 0.81; P = 0.03) than AT1RAb− persons not prescribed an ACEi. AT1RAb was prevalent among hypertensive adults and was associated with higher BP among persons on an ARB.

30 March 2023 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
FAFlor Alvarado
Flor Alvarado
CDCynthia Delgado
Cynthia Delgado
SNSusanne B. Nicholas
Susanne B. Nicholas
AJAllison Jaure
Allison Jaure
LCLilia Cervantes
Lilia Cervantes
Background: Latinx individuals are disproportionally burdened by kidney diseases compared to non-Latinx White individuals and are underrepresented in kidney-related research. We aimed to describe stakeholder perspectives on Latinx patient engagement in kidney-related research. Methods: We conducted a thematic analysis of two online moderated discussions and an interactive online survey with open-text responses involving participants (i.e. stakeholders), with personal and/or professional experiences with Latinx patients with kidney diseases and their families/caregivers. Results: Among the eight stakeholders (Female:75%; Latinx ethnicity:88%), there were three physicians, one nurse, one patient with kidney disease who received a kidney transplant, one policy maker, one Doctor of Philosophy, and one executive director of a non-profit health organization. We identified five themes. The majority of themes and their respective subthemes (in parentheses) reflected barriers to engagement: Lack of personal relevance (unable to relate to research staff and marketing resources, and unclear benefit of research to self, family, and community); fear and vulnerability (immigration concerns, stigma with seeking care, skepticism of Western medicine); logistical and financial barriers (limited opportunities to enroll in clinical trials, out-of-pocket costs, transportation issues); and distrust and asymmetry of power (related to limited English proficiency or health literacy, and provider bias). The last theme centered on stimulating interest and establishing trust in the research process. Conclusions: To overcome barriers to engagement in kidney-related research and establish trust among potential Latinx research participants, stakeholders recommended employing cultural responsiveness and community-based strategies. These strategies can help identify local health priorities, enhance research recruitment and retention strategies, and establish partnerships that continue to elevate research endeavors aiming to enhance the health of Latinx individuals with kidney diseases.

1 May 2021 in Kidney Medicine
Verified
Journal Article
Open access
FAFlor Alvarado
Flor Alvarado
DCDeidra C. Crews
Deidra C. Crews
CDCynthia Delgado
Cynthia Delgado
JNJavier A. Neyra
Javier A. Neyra

15 February 2023 in American Heart Journal Plus: Cardiology Research and Practice
Verified
Journal Article
Open access
FAFlor Alvarado
Flor Alvarado
AHAmanda Hercules
Amanda Hercules
MWMelanie Wanigatunga
Melanie Wanigatunga
JLJodie Laurent
Jodie Laurent
MPMarilyn Payne
Marilyn Payne
KFKeith C. Ferdinand
Keith C. Ferdinand
Few church-based health interventions have evaluated the influence of neighborhood-level social determinants of health (SDOH) on adopting heart-healthy lifestyles; none has occurred in Louisiana. We aimed to characterize neighborhood-level SDOH that may influence the ability to adopt a heart-healthy lifestyle among Black community church members in New Orleans, LA. This mixed methods study used quantitative data (surveys) and qualitative data (focus groups) to explore SDOH at the neighborhood- and church-area- level, including factors related to the physical (e.g., walkability, accessibility to recreational facilities) and social (e.g., social cohesion, perceived safety) environments. Descriptive analyses were conducted for quantitative data. Qualitative data were coded and analyzed using grounded theory and thematic analysis. Among survey respondents (n = 302, 77 % female, 99 % Black), most reported having walkable neighborhood sidewalks and high neighborhood social cohesion. Two-thirds did not feel violence was a problem in their neighborhood and felt safe walking, day, or night. Focus group participants (n = 27, 74 % female, 100 % Black) reported facilitators to heart-healthy living, including social support promoting physical activity, intentionality in growing, buying, and preparing produce, and the neighborhood-built environment. Reported barriers included: crime, the COVID-19 pandemic, individual-level factors limiting physical activity, and city-wide disparities influencing health. Participants discussed strategies to promote healthy living, centered around the theme of establishing and rebuilding community relationships. Future health interventions aimed at improving cardiovascular outcomes among church communities should continue to inquire about neighborhood-level SDOH and tailor interventions, as appropriate, to address barriers and leverage facilitators within these communities.

21 May 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
QCQiuyu Cao
Qiuyu Cao
YBYufang Bi
Yufang Bi
FAFlor Alvarado
Flor Alvarado
AAAmanda H. Anderson
Amanda H. Anderson
KMKatherine Teresa Mills
Katherine Teresa Mills
MUMark L. Unruh
Mark L. Unruh
Background: Higher cardiovascular health (CVH) score is associated with lower risks of cardiovascular disease (CVD) and mortality in the general population. However, it is unclear whether cumulative CVH is associated with CVD, end‐stage kidney disease (ESKD), and death in patients with chronic kidney disease. Methods and Results: Among individuals from the prospective CRIC (Chronic Renal Insufficiency Cohort) Study, we used the percentage of the maximum possible CVH score attained from baseline to the year 5 visit to calculate cumulative CVH score. Multivariable‐adjusted Cox proportional hazards regression was used to investigate the associations of cumulative CVH with risks of adjudicated CVD (myocardial infarction, stroke, and heart failure), ESKD, and all‐cause mortality. A total of 3939 participants (mean age, 57.7 years; 54.9% men) were included. The mean (SD) cumulative CVH score attained during 5 years was 55.5% (12.3%). Over a subsequent median 10.2‐year follow‐up, 597 participants developed CVD, 656 had ESKD, and 1324 died. A higher cumulative CVH score was significantly associated with lower risks of CVD, ESKD, and mortality, independent of the CVH score at year 5. Multivariable‐adjusted hazard ratios and 95% CIs per 10% higher cumulative CVH score during 5 years were 0.81 (0.69–0.95) for CVD, 0.82 (0.70–0.97) for ESKD, and 0.80 (0.72–0.89) for mortality. Conclusions: Among patients with chronic kidney disease stages 2 to 4, a better CVH status maintained throughout 5 years is associated with lower risks of CVD, ESKD, and all‐cause mortality. The findings support the need for interventions to maintain ideal CVH status for prevention of adverse outcomes in the population with chronic kidney disease.